34 active not recruiting. 34 Phase 2, 7 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 34 | Active not recruiting 34 |
| Phase 1 | 7 | Active not recruiting 7 |
| Phase 3 | 3 | Active not recruiting 3 |
Follow Lung Diseases, Obstructive: new trials by email Literature Review of Lung Diseases, Obstructive trials Research Report on Lung Diseases, Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD) HSK39004 Dry Powder Inhaler-0.75mg, HSK39004 Dry Powder Inhaler-1.5mg, HSK39004 Dry Powder Inhaler Simulant - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Active not recruiting | Haisco Pharmaceutical Group Co., Ltd. | 180 | 2025-08-13 | 2026-04-08 |
| A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD Verekitug, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Active not recruiting | Upstream Bio Inc. | 666 | 2025-07-02 | 2026-07-20 |
| A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD INCA034176 - Chronic Graft-versus-host-disease | Phase 1 / Phase 2 | Active not recruiting | Incyte Corporation | 32 | 2025-06-25 | 2026-08-10 |
| Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD Placebo, Treprostinil Inhalation Solution 36 mcg, Treprostinil Inhalation Solution 78 mcg - COPD (Chronic Obstructive Pulmonary Disease) | Phase 2 | Active not recruiting | University of Alberta | 20 | 2025-06-05 | 2026-11-05 |
| A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) Verekitug, Placebo - Severe Asthma | Phase 2 | Active not recruiting | Upstream Bio Inc. | 396 | 2025-05-21 | 2026-05-14 |
| Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects MG-ZG122 Humanized Monoclonal Antibody Injection, Placebo - Bronchial Asthma | Phase 2 | Active not recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 160 | 2025-05-11 | 2025-07-08 |
| A Clinical Study to Evaluate the Efficacy and Safety of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease TQC2938 injection, TQC2938 injection Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 256 | 2025-03-17 | 2026-04-07 |
| Local Antibiotic Delivery for Community Acquired Pneumonia Levofloxacin, Placebo - Community Acquired Pneumonia (CAP) | Phase 2 / Phase 3 | Active not recruiting | Copenhagen Respiratory Research | 36 | 2025-03-04 | 2026-11-06 |
| A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma GSK5784283, Placebo - Asthma | Phase 2 | Active not recruiting | GlaxoSmithKline | 307 | 2025-02-10 | 2026-10-26 |
| A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease TQC2731 injection, TQC2731 Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 | Active not recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 258 | 2024-12-31 | 2025-12-12 |
| A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma 610, Placebo - Asthma | Phase 2 | Active not recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 225 | 2024-12-20 | 2026-01-29 |
| Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma Lunsekimig, Short-Acting Beta Agonists (SABA), Placebo - Asthma | Phase 2 | Active not recruiting | Sanofi | 556 | 2024-11-07 | 2026-09-22 |
| Oral Intake of Mg in Controlled Asthmatic Patients Magnesium, ICS+LABA - Bronchial Asthma | Phase 2 / Phase 3 | Active not recruiting | Zagazig University | 166 | 2024-11-02 | 2025-08-14 |
| A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease Axatilimab, Ruxolitinib, Corticosteroids - Chronic Graft-versus-host-disease | Phase 2 | Active not recruiting | Incyte Corporation | 130 | 2024-10-11 | 2026-10-15 |
| A Study to Evaluate Solrikitug in Participants With COPD (ZION) Biological: Solrikitug low dose, Biological: Solrikitug high dose, Placebo - COPD | Phase 2 | Active not recruiting | Uniquity One (UNI) | 182 | 2024-08-14 | 2026-10-28 |
| A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD Dexpramipexole Dihydrochloride - Chronic Obstructive Pulmonary Disease | Phase 2 | Active not recruiting | Areteia Therapeutics | 30 | 2024-07-09 | 2025-05-14 |
| TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD)) TDI01 suspension - GVHD, Chronic | Phase 1 / Phase 2 | Active not recruiting | Beijing Tide Pharmaceutical Co., Ltd | 60 | 2024-02-06 | 2025-09-26 |
| Intracerebral Transplantation of Autologous MSC Combined With Scaffold Product for Chronic Intracerebral Hemorrhage HUFF-01 - Intracerebral Hemorrhage | Phase 1 / Phase 2 | Active not recruiting | Hokkaido University Hospital | 8 | 2023-12-01 | 2026-10-15 |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma povorcitinib, placebo, ICS-LABA - Moderate to Severe Asthma | Phase 2 | Active not recruiting | Incyte Corporation | 247 | 2023-07-11 | 2026-07-07 |
| Dupilumab Effects Against Aeroallergen Challenge Dupilumab, House Dust Mites (HDM), Placebo - Asthma, Allergic | Phase 2 | Active not recruiting | The University of Texas Health Science Center at San Antonio | 96 | 2023-03-29 | 2026-08-11 |
Showing 20 of 34. Sign in to see all of them.
Asthma (15) · Pulmonary Disease, Chronic Obstructive (11) · Bronchiolitis Obliterans Syndrome (9) · Emphysema (2) · Lung Diseases (2) · Anemia, Refractory, with Excess of Blasts (1) · Aspergillosis, Allergic Bronchopulmonary (1) · Bronchial Diseases (1) · Bronchitis, Chronic (1) · Burns (1) · Cerebral Hemorrhage (1) · Community-Acquired Pneumonia (1) · Diabetic Foot (1) · Dust Mite Allergy (1) · Dyspnea (1)
Respiratory Tract Diseases (33) · Lung Diseases (32) · Bronchial Diseases (24) · Immune System Diseases (24) · Hypersensitivity (15) · Hypersensitivity, Immediate (15) · Respiratory Hypersensitivity (15) · Pathological Conditions, Signs and Symptoms (13) · Pathologic Processes (12) · Chronic Disease (11) · Disease Attributes (11) · Bronchitis (10) · Bronchiolitis (9) · Bronchiolitis Obliterans (9)
Prednisolone (2) · axatilimab (2) · dupilumab (2) · Adrenal Cortex Hormones (1) · Albuterol (1) · Antigens, Dermatophagoides (1) · Antilymphocyte Serum (1) · Budesonide (1) · Budesonide, Formoterol Fumarate Drug Combination (1) · Cyclophosphamide (1) · Fluticasone (1) · Fluticasone-Salmeterol Drug Combination (1) · Formoterol Fumarate (1) · GSK573719 (1) · Interleukin-2 (1)
Incyte Corporation (3) · Upstream Bio Inc. (2) · Areteia Therapeutics (1) · Beijing Tide Pharmaceutical Co., Ltd (1) · Boston Children's Hospital (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1) · Copenhagen Respiratory Research (1) · Dana-Farber Cancer Institute (1) · GlaxoSmithKline (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Hokkaido University Hospital (1) · McMaster University (1) · Merck Sharp & Dohme LLC (1) · National Cancer Institute (NCI) (1)
United States (20) · China (9) · Canada (7) · Germany (7) · Spain (7) · United Kingdom (7) · Argentina (5) · Japan (5) · Italy (4) · Poland (4) · Australia (3) · Belgium (3) · Bulgaria (3) · Chile (3) · Czechia (3)
Justin Salciccioli, MD (2) · Andrew W Lee, MD (1) · Daniel J. Jackson, M.D. (1) · Gerard J Criner, MD (1) · Irwin R Walker, MBBS (1) · James G Krings, MD MSc (1) · Jens-Ulrik S. Jensen, Professor, MD, phD (1) · John Koreth, MBBS, DPhil (1) · Katherine Cahill, MD (1) · Kristjan Paulson, MD (1) · Kun Qing, PhD (1) · Michael Stickland (1) · Michael Wechsler, MD (1)
PMID 23681559, PMID 25146558, PMID 30954166, PMID 32453217, PMID 33242697, PMID 34398099, PMID 36471430, PMID 40009501, PMID 41567689, PMID 42629427
2025 (1), KL2TR002346 (1), P01CA142106 (1), U01AI155299 (1), U01AI158460 (1), U01AI179563 (1), UL1TR002345 (1)